FDA slams Eli Lil­ly's 'mis­lead­ing' In­sta­gram ad for its type 2 di­a­betes in­jec­tion

In a first for 2022, the FDA’s Of­fice of Pre­scrip­tion Drug Pro­mo­tion has is­sued an un­ti­tled let­ter, which was re­cent­ly sent to Eli Lil­ly over what the agency calls a “mis­lead­ing” and “par­tic­u­lar­ly con­cern­ing” In­sta­gram ad the com­pa­ny post­ed for its type 2 di­a­betes drug Trulic­i­ty.

The ques­tion­able In­sta­gram post, which has since been delet­ed by Lil­ly, failed to ad­e­quate­ly com­mu­ni­cate the in­di­ca­tion and lim­i­ta­tions of use as­so­ci­at­ed with Trulic­i­ty, FDA says.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER